Abstract | BACKGROUND: METHODS: Rabbits were inoculated intraperitoneally with 10(8) cfu/mL of VIM-1-positive E. coli and were assigned to receive no treatment (controls) or intravenous imipenem/cilastatin ( imipenem) 70 mg/kg/12 h or meropenem 125 mg/kg/12 h or ertapenem 60 mg/kg/12 h or aztreonam 70 mg/kg/12 h. Dosing regimens were chosen on the basis of preliminary pharmacokinetic studies so that T(>MIC) was achieved for ≥50% of the dosing interval for all tested antibiotics. A total of eight doses were administered before sacrifice and the abscesses were harvested and quantitatively cultured. RESULTS: MICs of imipenem, meropenem, ertapenem and aztreonam for the infecting isolate were 1, ≤0.25, 1.5 and ≤0.25 mg/L, respectively. The log(10) cfu/g (mean ± SD) viable counts in pus were as follows: controls (n = 16), 8.71 ± 1.34 (P < 0.001 versus all other groups); imipenem (n = 15), 4.89 ± 2.42; meropenem (n = 15), 4.24 ± 2.44; ertapenem (n = 16), 3.17 ± 1.85 (P = 0.022 versus imipenem); and aztreonam (n = 15), 3.62 ± 3.05. Mortality among treated rabbits was significantly reduced compared with controls. Four animals in the aztreonam group (26.7%) had culture-negative pus and no mortality was noted among aztreonam-treated animals. CONCLUSIONS: In the rabbit experimental model, carbapenems were shown to be effective in the treatment of intra-abdominal infection due to an extended-spectrum β-lactamase-negative carbapenem-susceptible VIM-1-producing clinical E. coli strain, but treatment with aztreonam resulted in a more favourable outcome overall.
|
Authors | Maria Souli, Eleftheria Konstantinidou, Ira Tzepi, Thomas Tsaganos, Angelos Pefanis, Zoi Chryssouli, Irene Galani, Evangelos Giamarellos-Bourboulis, Helen Giamarellou |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 66
Issue 3
Pg. 611-7
(Mar 2011)
ISSN: 1460-2091 [Electronic] England |
PMID | 21177674
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Carbapenems
- beta-Lactamases
|
Topics |
- Abdominal Abscess
(drug therapy)
- Animals
- Anti-Bacterial Agents
(administration & dosage, pharmacology)
- Carbapenems
(administration & dosage, pharmacology)
- Disease Models, Animal
- Escherichia coli
(drug effects, enzymology, isolation & purification)
- Escherichia coli Infections
(drug therapy, microbiology)
- Humans
- Male
- Rabbits
- Rodent Diseases
(drug therapy)
- Treatment Outcome
- beta-Lactamases
(biosynthesis)
|